Table 1.
Univariate and multivariate analysis of known clinicopathological risk factors and post-ACT ctDNA associated with RFS (n = 49)
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P-value | HR | 95%CI | P-value | |
| Age, years (< 60/ ≥ 60) | 1.527 | 0.652-3.575 | 0.329 | NA | ||
| Gender (female/male) | 1.767 | 0.781-4.002 | 0.172 | NA | ||
| Primary tumor (Right/Left) | 0.865 | 0.279-2.679 | 0.801 | NA | ||
| Nodal involvement of primary tumor (No/Yes) | 0.614 | 0.283-1.336 | 0.219 | NA | ||
| Time between primary tumor and liver metastases (< 12/ ≥ 12months) | 0.766 | 0.293-2.003 | 0.587 | NA | ||
| Diameter of the largest LM (< 5/ ≥ 5cm) | 1.412 | 0.620-3.219 | 0.412 | NA | ||
| Preoperative CEA level (< 5/ ≥ 5ng / mL) | 1.152 | 0.446-2.977 | 0.770 | NA | ||
| Number of LM (< 2/ ≥ 2) | 0.476 | 0.211-1.075 | 0.074 | NA | ||
| CRS (0-2/3-5) | 0.656 | 0.311-1.382 | 0.267 | NA | ||
| Preoperative chemotherapy (Yes/No) | 1.936 | 0.684-5.479 | 0.211 | NA | ||
| Postoperative chemotherapy (Yes/No) | 0.072 | 0.005-1.022 | 0.0519 | NA | ||
| Concomitant ablation (Yes/No) | 1.186 | 0.485-2.902 | 0.709 | NA | ||
| KRAS (mt-/mt+) | 0.944 | 0.418-2.130 | 0.889 | NA | ||
| BRAF (mt-/mt+) | 1.248 | 0.207-7.520 | 0.809 | NA | ||
| Post-ACT ctDNA (Negative/Postive, n = 49) | 0.406 | 0.189-0.873 | 0.021 | 0.417 | 0.194-0.896 | 0.025 |
HR greater and less than 1 indicates increased and decreased relapse risk, respectively.
HR: hazard ratio; RFS: recurrence-free survival; CRS: clinical risk score; post-ACT: postoperative adjuvant chemotherapy; ctDNA: circulating tumor DNA.